openPR Logo
Press release

DERMADRY'S ANTI-SWEAT DEVICE RECEIVES FDA CLEARANCE

03-12-2020 09:09 AM CET | Health & Medicine

Press release from: Dermadry

The U.S. Food and Drug Administration (FDA) has cleared an innovative new device for the treatment of hyperhidrosis (excessive sweating) in the United States.

The device, created by Canadian manufacturer Dermadry, has been on the market since receiving its medical device license from Health Canada in October 2018. Since this time, Dermadry has received daily inquiries regarding the availability of its device in the United States, signaling a major need for this type of treatment in the U.S., which was not previously adequately met. The news of the FDA clearance of Dermadry's anti-sweat device puts an end to these inquiries, as the presale of the device was made available to U.S. residents on the 26th of February.

Dermadry was developed by a team of hyperhidrosis sufferers and is now the best-selling iontophoresis machine worldwide. Dermadry is proud to add its FDA clearance to its long list of certifications and compliances worldwide, which also includes a license from the Australian Therapeutic Goods Administration (TGA), as the company has prioritized safety and efficiency since its early development stages.

Hyperhidrosis: The Silent Handicap

Hyperhidrosis is a medical condition that causes sweating 4-5 times in excess of the body's thermoregulation needs. It is reported estimated to affect over 5% of the American population or 1 in 20 Americans. This reported prevalence is thought to be a much lower figure than the actual number of people affected, as hyperhidrosis is a misunderstood and underreported condition. Those affected often do not seek medical attention and often live their life in discomfort and embarrassment due to shame or simple lack of awareness, despite hyperhidrosis being a highly treatable condition.

The Solution: The Anti-Sweat Device

Iontophoresis is a natural, non-invasive, drug-free, and needle-free treatment option for hyperhidrosis patients. Dermadry is proud to offer an all-in-one device that has been developed to target and treat excessive sweating of the hands, feet, and underarms.
This home-use new device facilitates treatment by allowing patients to treat excessive sweating from their home using only tap water, and create their own treatment schedule to fit their lifestyle and needs. It eliminates the need for painful and invasive procedures, as well as recurrent costs and clinic visits.

Dermadry's Launch in the USA

To celebrate Dermadry's launch in the United States, the Canadian company has partnered with U.S. telemedicine provider SkyMD , which enables patients to receive a diagnosis and prescription online. As all iontophoresis machines require a prescription in the U.S., this service enables users to get a dermatology consultation online, making it easier and more convenient than ever before to get the required prescription.

This is the first of many exciting collaborations the company is working on. In the upcoming months, Dermadry will be bringing its device to medical conferences and events across the U.S., furthering its mission to raise awareness of hyperhidrosis and iontophoresis treatment.

Going forward, the ambitious company is already looking to obtain more worldwide certifications, in order to make their device available to more people globally. Dermadry is excited to be entering the U.S. market and helping residents across the country obtain the dryness, comfort, and confidence they deserve.

Dermadry Laboratories Inc
9223 Boul Langelier, Saint-Leonard, QC H1P 3K9
For any media inquiries, please contact media@dermadry.com
https://www.dermadry.com/

Dermadry is a Canadian medical device company headquartered in Montreal, Quebec. They manufacture an FDA cleared iontophoresis device that treats hyperhidrosis, a medical condition characterized by excessive sweating. They are committed to educating the public on the condition and improving the lives of the millions affected worldwide.

Learn more at dermadry.com and on social media @dermadry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release DERMADRY'S ANTI-SWEAT DEVICE RECEIVES FDA CLEARANCE here

News-ID: 1962831 • Views: 201

More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
US FDA Prohibits 19 Antibacterial Soap Ingredients
The US Food and Drug Administration (FDA) has issued a final rule regarding 19 ingredients in over-the-counter (OTC) consumer antiseptic products intended for use with water. The FDA has now determined that these 19 ingredients are not generally recognized as safe and effective (GRAS/GRAE) and so, without an approved new drug application, products containing these ingredients are now considered misbranded – effective September 6, 2017. The US FDA issued its final
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding
MetaFix™ PlantarMAX™ Foot Plate received FDA-Release
Merete Medical GmbH announces the FDA-approval for MetaFix™ PlantarMAX™ plate. PlantarMAX™ is designed as the first plantar/medial Lapidus fixation plate which takes advantage of the biomechanically superior fixation on the tension side of the Metatarsal/Cuneiform joint during a Lapidus Hallux Valgus correction procedure. The fixation on the tension side of the joint is superior to dorsal or medial fixation and offers additional compression as the patient proceeds to weight bearing. Merete